"instanceType","rationale","uuid:ID","id","versionIdentifier"
"StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","cc489f70-a884-4aea-a99e-d007b9c81e4e","StudyVersion_1","2"
